External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Decisive Steps on Italy and China Facilities: For the past few quarters, CFS has been incurring significant costs in its Italian (Diphenol) and Chinese facilities without any corresponding revenues.</li><li>The company has now concluded that repurposing these facilities is not economically feasible and has entirely impaired these assets.</li><li>While this has impacted the profit during the quarter (exceptional expenses of Rs 151 Cr), it provides much-needed clarity on the future plans. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Decisive Steps on Italy and China Facilities: For the past few quarters, CFS has been incurring significant costs in its Italian (Diphenol) and Chinese facilities without any corresponding revenues.The company has now concluded that repurposing these facilities is not economically feasible and has entirely impaired these assets.While this has impacted the profit during the quarter (exceptional expenses of Rs 151 Cr), it provides much-needed clarity on the future plans. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Camlin Fine Sciences Ltd - Looking for the Right Blend; Maintain HOLD